A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
Phase of Trial: Phase IV
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Vismodegib (Primary) ; Antineoplastics
- Indications Basal cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms RegiSONIC
- Sponsors Genentech
- 25 Jul 2017 Status changed from active, no longer recruiting to discontinued.
- 08 Mar 2016 Results of a preliminary sub-group analysis (n=88) presented at the 74th Annual Meeting of the American Academy of Dermatology
- 20 May 2015 According to Curis media release, data from this and other two trials ( see profile 209178 and 200209) will be presented at the Annual Meeting of American Society of Clinical Oncology (ASCO).